key: cord-0921071-mha7zs08 authors: Trivedi, Suvang; Miao, Congrong; Al-Abdallat, Mohammad M.; Haddadin, Aktham; Alqasrawi, Sultan; Iblan, Ibrahim; Nsour, Mohannad A.; Alsanouri, Tarek; Ali, Sami S.; Rha, Brian; Gerber, Susan I.; Payne, Daniel C.; Tamin, Azaibi; Thornburg, Natalie J. title: Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection date: 2017-09-26 journal: Journal of Medical Virology DOI: 10.1002/jmv.24948 sha: 4e1fc4e7215d17953628af3d41953acc1b942b03 doc_id: 921071 cord_uid: mha7zs08 The Centers for Disease Control and Prevention (CDC) algorithm for detecting presence of serum antibodies against Middle East Respiratory Syndrome coronavirus (MERS-CoV) in subjects with potential infections with the virus has included screening by indirect ELISA against recombinant nucleocapsid (N) protein and confirmation by immunofluorescent staining of infected monolayers and/or micro-neutralization titration. Other international groups include indirect ELISA assays using the spike (S) protein, as part of their serological determinations. In the current study, we describe development and validation of an indirect MERS-CoV S ELISA to be used as part of our serological determination for evidence of previous exposure to the virus. Recombinant MERS-N was produced in BL21 cells as described previously. 2 MERS-N ELISAs were also performed as previously described. 2 For Western blot analysis, 1 μg purified N, pET control lysate, or 0.5 μg purified S was run on an SDS page and transferred to a PVDF membrane. Sera, without MER-CoV reactivity (NHS) and against SARS, 229E, OC43, HKU1, and MERS-CoV, diluted at 1:400 were used to probe the blots with HRP goat anti human IgA, IgG, IgM (H and L). The blot was developed with DAB. Receiver-operating characteristic (ROC) analysis was used to determine diagnostic sensitivity, specificity, and optimal test cut-off OD values, of the assay using Excel and IBM SPSS Statistics 21 softwares. 12, 13 Briefly, diagnostic sensitivity (%Se) and specificity (%Sp) of ELISA test results were calculated using microneutralization results as reference gold standard test for MERS-CoV positive and negative samples. Optimal test cut-off OD values were ascertained by plotting %sensitivity (%Se) and %specificity (%Sp) against ELISA cut-off OD values as Two Graph-ROC plots and the intersection of the two curves was determined to be cut-off OD for ELISA. Using commercially prepared purified ectodomain MERS-CoV S, we optimized coating and blocking conditions for an indirect ELISA using known MERS-CoV negative and positive human sera (data not shown). After optimization, we tested sera from 400 normal human donors and Figure 1A ). Using an OD cutoff of 0.2, one of the 400 normal human sera (0.25%) was above cutoff. In order to precisely test the specificity and sensitivity of the S ELISA, nine true negative sera with reciprocal endpoint microneutralization titers less than 20 and nine true positive sera with reciprocal endpoint microneutralization titers ranging from 20 to 640, were tested at dilutions of 200, 400, 800, and 1600 ( Figure 1B) . ROC analysis was performed to calculate the diagnostic sensitivity (true positive) and specificity (true negative) of the assay. At a standard screening dilution of 1:400, the sensitivity of the S ELISA remained at 89% or greater at ODs <0.51 ( Figure 1C) . Specificity increased to 89% at an OD of 0.09 and 100% at 0.39 ( Figure 1C ). At serum dilutions of 1:800 and 1:1600, the S ELISA remains highly specific, but loses sensitivity at higher ODs as can be expected (Figures 1D and 1E) . and N, at lower ODs, the S ELISA is more specific, while the N ELISA retains higher sensitivity across a large range of ODs. These data are not consistent with one publication examining serial blood draws from a single MERS-CoV patient has suggested their S ELISA is more sensitive than an N ELISA. 15 We have observed significant patient-to-patient differences in the quality and quantity of polyclonal antibody responses, and these conflicting data may be simply explained by human variation in immune response. suggested that S ELISA sensitivity can be increased by lowering the breakpoint in MERS-CoV S ELISAs. 16 While doing this would capture a larger percentage of patients who seroconvert, we have seen several patients who never develop detectable MERS-CoV S antibodies, but do develop N antibodies (data not shown). A second reason to retain both N and S ELISAS is there is evidence that antibodies against other coronavirus N proteins are detected earlier during infection than S proteins. Specifically, SARS-CoV infection studies have indicated that antibodies against the N protein appear before antibodies against the S protein. 17, 18 We frequently receive serum from patients who are acutely ill with suspected MERS- Third, while N ELISA may be more sensitive, examination of N and S cross reactivities suggest that antibodies directed against N, but not S, may cross react with within-group coronaviruses, 19 therefore using both N and S ELISAS may capture both sensitivity and specificity information. As part of our screening process, we aim to capture as many potential positive serum as possible, and then perform confirmatory assays. In summary, during our new testing algorithm, both N and S ELISAS will be used as screening assays with sera diluted to 1:400. For all sera with ODs above assay cutoff, they will be diluted serially, fourfold from 1:100-1:6400 and used for endpoint titer determinations. Sera that are positive for either N or S or both N and S (titers at 1:400, 1:1600, or 1:6400), will be tested via microneutralization with live MERS-CoV along with 10% of negative sera. We will define positive MERS-CoV serology as positive in two of three assays tested, N ELISA, S ELISA, and microneutralization or positive by microneutralization alone with microneutralization activity as confirmed positive. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of The Centers for Disease Control and Prevention/the National Center for Immunization and Middle East respiratory syndrome coronavirus (MERS-CoV Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description The role of laboratory diagnostics in emerging viral infections: the example of the Middle East respiratory syndrome epidemic Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity Serological assays for emerging coronaviruses: challenges and pitfalls Infectious middle east respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia Kinetics of serologic responses to MERS Coronavirus infection in humans Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus to the United States Persistence of antibodies against middle east respiratory syndrome coronavirus Two-graph receiver operating characteristic (TG-ROC): a Microsoft-EXCEL template for the selection of cut-off values in diagnostic tests A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses ORCID Natalie J. Thornburg http://orcid.org/0000-0003-3523-3616